. 2019 May 22;8(5):493. doi: 10.3390/cells8050493

Table 1.

Expression levels of mitophagy regulators in samples from cancer patients. The levels of regulation are defined by the correlation of the expression levels with cancer progression and/or poor prognosis.

Protein	Expression Levels in Patients	Cancer Type	Reference(s)
Mitochondrial Dynamics
MFN 1	Downregulation	Triple Negative Breast Cancer ^1,2, Hepatocellular Carcinoma ^1,2	[89,90]
MFN 2	Upregulation	Cutaneous Melanoma ², Gastric Cancer ², Ovarian Cancer ¹, Prostate Cancer ²	[91,92,93,94]
MFN 2	Downregulation	Breast Cancer ^1,2, Hepatocellular Carcinoma ^1,2, Non-Small Cell Lung Cancer ¹	[95,96,97,98,99,100]
Opa1	Upregulation	Lung Cancer ^2,3, Colorectal Cancer ¹	[101,102,103]
Opa1	Downregulation	Hepatocellular Carcinoma ²	[104]
DRP1	Upregulation	Triple Negative Breast Cancer ^1,2, Colorectal Cancer¹, Hepatocellular Carcinoma ^1,2, Ovarian Cancer ^1,3	[89,90,101,105]
DRP1	Downregulation	Colorectal Cancer ², Lung Cancer ²	[106]
pDRP1 (Ser616)	Upregulation	Colorectal Cancer ², Melanoma ²	[107,108]
pDRP1 (Ser637)	Upregulation	Hepatocellular Carcinoma ²	[109]
Mff	Upregulation	Hepatocellular Carcinoma ^1,2	[110]
Mff	Downregulation	Tongue Squamous Cell Carcinoma ²	[111]
FIS1	Upregulation	Acute Myeloid Leukemia ^1,2, Oral Melanoma ², Prostate Cancer ¹	[93,112,113,114]
FIS1	Downregulation	Tongue Squamous Cell Carcinoma ²	[115]
Canonical Mitophagy Pathways
PINK1	Upregulation	Lung Cancer ², Esophageal Squamous Cell Carcinoma ²	[116,117]
PINK1	Downregulation	Ovarian cancer ¹	[118]
Parkin	Downregulation	Acute Lymphoblastic Leukemia ⁴, Colorectal Cancer ^1,2,4, Clear Cell Renal Cell Carcinoma ^1,2, Melanoma ^1,3, Oropharyngeal Squamous Cell Carcinoma ¹, Ovarian Cancer ^1,3, Pancreatic Cancer ^1,2,3	[119,120,121,122,123,124,125,126,127]
BNIP3	Upregulation	Adenoid Cystic Carcinoma ², Ampullary Carcinoma ², Breast Cancer ¹, Cervical Cancer ^1,2, Cholangiocarcinoma ², Colorectal Cancer ², Ependydoma ¹, Glioblastoma ², Lung Cancer ^1,2, Melanoma ², Ovarian Cancer ^1,2, Renal Carcinoma ^1,2, Uterine-Cervical Squamous Cell Carcinoma ¹	[128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143]
BNIP3	Downregulation	Bladder Cancer ⁴, Breast Cancer ^1,2, Colorectal Cancer ^2,4, Esophageal Cancer ⁴, Gastric Carcinoma ⁴, Laryngeal Squamous Cell Carcinoma ², Lung Cancer ⁴, Multiple Myeloma ^1,4, Pancreatic Cancer ^1,2,	[142,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163]
NIX	Upregulation	Breast Cancer ¹, Glioma ^1,2	[164,165]
NIX	Downregulation	Acute Myeloid Leukemia ¹, Prostate Cancer ³	[166,167]
FUNDC1	Upregulation	Breast Cancer ^1,2, Cervical Cancer ², Laryngeal Cancer ²	[168,169,170]
PGAM5	Upregulation	Hepatocellular Carcinoma ², Non-Small Cell Lung Cancer ²	[171,172]
Non-Canonical Mitophagy Pathways
CL	Upregulation	Prostate Cancer	[173,174]
CL	Downregulation	Hepatocellular Carcinoma	[175]
PHB2	Upregulation	Breast Cancer ^1,2, Colorectal Cancer ², Esophageal Squamous Cell carcinoma ^1,2, Leukemia ², Lymphoma ²	[167,176,177,178,179,180]
C18-Ceramide	Downregulation	Glioblastoma, Glioma, Head and Neck Squamous Cell Carcinoma	[181,182,183]
AMBRA1	Upregulation	Cholangiocarcinoma ², Gastric Adenocarcinoma ², Pancreatic Ductal Adenocarcinoma ², Prostate Cancer ^1,2	[184,185,186,187]
HUWE1	Upregulation	Lung Cancer ^1,2, Multiple Myeloma ¹	[188,189]
HUWE1	Downregulation	Breast Cancer ¹, Hepatocellular Carcinoma ¹, Osteosarcoma ¹	[190,191,192]
BCL2L13 (BCL-RAMBO)	Upregulation	Leukemia ¹	[193,194,195]
BCL2L13 (BCL-RAMBO)	Downregulation	Breast Cancer ¹, Locally Advanced Rectal Cancer ¹	[139,196]
RAB7	Upregulation	Oral Squamous Cell Carcinoma ², Prostate Cancer ¹,	[197,198]

¹ mRNA expression levels. ² Protein expression levels. ³ Copy Number Variation levels. ⁴ Promoter methylation levels.